Navigation Links
GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer
Date:10/15/2007

First FDA Approved Oral Therapy Will Allow Patients to be Treated for This

Aggressive Cancer at Home

PHILADELPHIA, Oct. 15 /PRNewswire-USNewswire/ -- GlaxoSmithKline (NYSE: GSK) announced today approval by the U.S. Food and Drug Administration (FDA) for oral HYCAMTIN(R) (topotecan) capsules for the treatment of relapsed small cell lung cancer (SCLC).

Specifically, HYCAMTIN capsules are indicated for patients who had a complete or partial response to first-line chemotherapy and who are at least 45 days from the end of that treatment. HYCAMTIN capsules are the only oral single-agent chemotherapy approved for the treatment of SCLC after failure of first-line therapy. The product will be available in 2008.

"The approval of HYCAMTIN capsules is particularly important for patients with relapsed small cell lung cancer as they now have an effective treatment option that has been shown to provide a survival benefit and can be conveniently taken at home," said Debasish Roychowdhury, M.D., Vice President, Global Clinical Development, Oncology Medicine Development Center, GSK. "Additionally, this milestone underscores GSK Oncology's commitment to helping improve cancer patients' quality of life."

This approval was based on positive results from a Phase III study comparing HYCAMTIN capsules plus best supportive care (BSC) to BSC alone in patients with relapsed SCLC, in addition to Phase II and Phase III supporting studies. Best supportive care refers to treatments intended to control, prevent and relieve disease complications to improve comfort and quality of life for the patient, but are not intended to have any anti-tumor effects. In the pivotal Phase III clinical trial, HYCAMTIN capsules added to BSC were associated with prolonged survival in patients with relapsed SCLC. This was the first randomized study ever to demonstrate that patients with relapsed SCLC live longer when they are treated with BSC and chemotherapy com
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
5. Point of Care Strep Tests Speed Treatment, Lower Costs
6. Rapid HIV Testing Increases Possibility of Treatment
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 26, 2014 Lexicon Pharmaceuticals, Inc. ... completion of previously announced concurrent financing transactions resulting ... and estimated offering expenses, Lexicon anticipates net proceeds ... transactions consisted of: , a public ... to a registration statement that has been declared ...
(Date:11/26/2014)... 2014 Investor-Edge has initiated coverage on ... Horizon Pharma PLC (NASDAQ: HZNP ), Endocyte Inc. ... JNJ ), and Theravance Inc. (NASDAQ: THRX ... at: http://investor-edge.com/register . On Tuesday, November 25, ... Dow Jones Industrial Average edged 0.02% lower, to finish the ...
(Date:11/26/2014)... -- Zynerba Pharmaceuticals , Inc., a specialty pharmaceutical ... cannabinoid treatments, today announced that the company will present ... The conference will be held December 2 to 3, ... York . Zynerba,s Chairman and CEO, Armando ... December 2. To listen to a webcast ...
Breaking Medicine Technology:Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2
... bioMerieux, a world leader in the field of in ... that most critical care nurses are unaware of a simple ... The survey, conducted at the 2010 American Association of Critical ... of nurses expressed the need for new tools to battle ...
... 21, 2010 INVO Bioscience, Inc. (OTC Bulletin Board: ... on treatment options for patients diagnosed with infertility, today ... Bolivia.  The initial order of INVOcell devices was purchased ... Under the direction of clinic director Dr. Joaquin Lopez ...
Cached Medicine Technology:Critical Care Nurses Do Not Have Access to Tools They Need to Treat Sepsis 2Critical Care Nurses Do Not Have Access to Tools They Need to Treat Sepsis 3INVO Bioscience Announces First Shipments of INVOcell Into Bolivia 2INVO Bioscience Announces First Shipments of INVOcell Into Bolivia 3
(Date:11/28/2014)... Pittsburgh, PA (PRWEB) November 28, 2014 An ... individuals have day to day. "I got this idea while ... walk to the bathroom," he said. , The Bed Buddy ... person to go to the bathroom. It eliminates the need ... well as promotes comfort and dignity. Easy to use and ...
(Date:11/28/2014)... 2014 ARTAS robotic hair transplant surgical ... time. PAI Medical Group hair transplant surgeons Chris Pawlinga, ... robotic hair transplant procedure in the Brentwood office on ... first in Tennessee and one of only three medical ... ARTAS robotic hair transplantation. Patients benefit from this minimally ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Based in ... organization focused on delivering exemplary solutions to the income ... ancillary benefits. In an effort to extend its reach ... and asset protection, Secura Consultants has brought aboard financial ... , “I am a big believer in specialization. When ...
(Date:11/28/2014)... TheBeautyPlace.com does it ... offering savings in abundance this retail season. , ... and cosmetic products such as SkinMedica, Neocutis, Glo ... competitive discounts on already reduced prices. At TheBeautyPlace.com ... giving customers savings year round. , TheBeautyPlace.com's Black ...
(Date:11/27/2014)... Albany, NY (PRWEB) November 28, 2014 ... industry is implant dentistry. The market for implant ... as supporting tools/instruments. The global market for dental ... and dental equipments. The dental equipment segment is ... with table of contents at: http://www.researchmoz.us/global-dental-market-report-2014-edition-report.html ...
Breaking Medicine News(10 mins):Health News:First in Tennessee - PAI Medical Group Announces ARTAS - The World’s Most Advanced Medical Robot Used for Hair Transplant Surgery 2Health News:Matt Lee, CLU, ChFC Joins Secura Consultants as New Brokerage Consultant 2Health News:TheBeautyPlace.com Announces Double Savings 2Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 2Health News:Dental Market Research Report 2014 - Global Industry Size, Share, Trends, Growth, Retail Sales Value and Forecast by Researchmoz.us 3
... A device consisting of a giant rubber tube may hold ... sea waves. , Invented in the UK, the ,Anaconda, is ... it would be cheap to manufacture and maintain, enabling it ... of wave energy converter. Cost has been a key barrier ...
... BEACH, Va., July 3 AMERIGROUP,Corporation (NYSE: AGP ... renewed its contract with the State of Tennessee,through June ... for the period April 1, 2008,through June 30, 2008, ... July 1,2008 through June 30, 2009. Expenditures on home ...
... July 3 Mylan Inc. (NYSE: MYL ... has,received tentative approval from the U.S. Food and ... (ANDA) for Linezolid,Tablets, 600 mg., Linezolid Tablets, ... Upjohn,s Zyvox(R) Tablets, which had U.S. sales of ...
... Rigel Pharmaceuticals,Inc. (Nasdaq: RIGL ) today announced that ... will present a company overview,at the Fourth Annual Collins ... a.m. EDT at The Mandarin Oriental Hotel in New ... or the subsequent archived recording,log on to http://www.rigel.com ...
... AND DUSK, DRAIN, SACRAMENTO, Calif., July 2 ... families and friends gathering outdoors, the,Mosquito and Vector ... take precautions against West Nile virus., "Individuals ... to prevent the spread of West Nile Virus ...
... long-term studies to assure medications don,t raise cardiovascular risks, ... to control type 2 diabetes should be subjected to ... the risk of heart problems, U.S. Food and Drug ... experts voted 14-to-2, at the end of a two-day ...
Cached Medicine News:Health News:Rubber 'snake' could help wave power get a bite of the energy market 2Health News:AMERIGROUP Renews Contract with Tennessee 2Health News:Remember West Nile Virus Safety This Fourth of July 2Health News:FDA Panel Calls for More Testing of Diabetes Drugs 2Health News:FDA Panel Calls for More Testing of Diabetes Drugs 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: